{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:10:23Z","timestamp":1780758623478,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["GPP2022"],"award-info":[{"award-number":["GPP2022"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.trre.2025.100958","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:09:23Z","timestamp":1753974563000},"page":"100958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The impact of standard- versus reduced-dose tacrolimus exposure on clinical outcomes in adult kidney transplant recipients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"given":"Suwasin","family":"Udomkarnjananun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangil","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Phan Hai","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongji","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2025.100958_bb0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","article-title":"The many faces of calcineurin inhibitor toxicity-what the FK?","volume":"27","author":"Farouk","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.trre.2025.100958_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2478\/abm-2024-0015","article-title":"A review of landmark studies on maintenance immunosuppressive regimens in kidney transplantation","volume":"18","author":"Udomkarnjananun","year":"2024","journal-title":"Asian Biomed (Res Rev News)"},{"key":"10.1016\/j.trre.2025.100958_bb0015","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1681\/ASN.2014121234","article-title":"Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients","volume":"26","author":"Hricik","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2025.100958_bb0020","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2025.100958_bb0025","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100958_bb0030","article-title":"Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients","volume":"7","author":"Karpe","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2025.100958_bb0035","first-page":"11:90","article-title":"Long-term tacrolimus blood trough level and patient survival in adult liver transplantation","author":"Hsiao","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.trre.2025.100958_bb0040","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2025.100958_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"19","author":"Lucey","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2025.100958_bb0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","article-title":"Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) group","volume":"101","author":"Neuberger","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100958_bb0055","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1097\/JS9.0000000000001800","article-title":"Optimum tacrolimus trough levels for enhanced graft survival and safety in kidney transplantation: a retrospective multicenter real-world evidence study","volume":"110","author":"Han","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.trre.2025.100958_bb0060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.transproceed.2019.11.003","article-title":"Long-term kidney transplant outcomes: role of prolonged-release tacrolimus","volume":"52","author":"Banas","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2025.100958_bb0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12882-021-02622-5","article-title":"Tacrolimus trough levels in kidney transplant recipients","volume":"22","author":"Hwang","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.trre.2025.100958_bb0070","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ki.2013.484","article-title":"Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation","volume":"85","author":"van Gelder","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2025.100958_bb0075","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2025.100958_bb0080","author":"National Institute for Health and Care Research"},{"key":"10.1016\/j.trre.2025.100958_bb0085","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.trre.2025.100958_bb0090","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/tri.13581","article-title":"Immunosuppression with generic tacrolimus in liver and kidney transplantation-systematic review and meta-analysis on biopsy-proven acute rejection and bioequivalence","volume":"33","author":"Kahn","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2025.100958_bb0095","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2025.100958_bb0100","series-title":"The GRADE book","author":"The GRADE Working Group","year":"2024"},{"key":"10.1016\/j.trre.2025.100958_bb0105","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/TP.0b013e31817442cf","article-title":"Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results","volume":"86","author":"Bolin","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100958_bb0110","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/ajt.14109","article-title":"Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study","volume":"17","author":"Gatault","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100958_bb0115","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14655","article-title":"Two-year outcomes of low-exposure extended-release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: a multi-center randomized controlled trial","volume":"36","author":"Hidaka","year":"2022","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2025.100958_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000877","article-title":"Safety and efficacy of reduced prolonged-release tacrolimus exposure in de novo kidney transplantation: a randomized, open-label, pilot study in Asia-OPTIMIZE study","volume":"5","author":"Kim","year":"2019","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2025.100958_bb0125","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.14504","article-title":"Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation","volume":"18","author":"Davis","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100958_bb0130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/tri.12699","article-title":"Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation","volume":"29","author":"Gaynor","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2025.100958_bb0135","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/FTD.0000000000000593","article-title":"Tacrolimus trough level at the first month may predict renal transplantation outcomes among living Chinese kidney transplant patients: a propensity score-matched analysis","volume":"41","author":"Yin","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2025.100958_bb0145","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1111\/j.1600-6143.2011.03718.x","article-title":"Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy","volume":"11","author":"Snanoudj","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100958_bb0150","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1111\/j.1600-6143.2011.03719.x","article-title":"Histological characteristics of calcineurin inhibitor toxicity--there is no such thing as specificity!","volume":"11","author":"Mengel","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100958_bb0155","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1600-6143.2010.03312.x","article-title":"The histology of solitary renal allografts at 1 and 5 years after transplantation","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100958_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663602","article-title":"Conversion from calcineurin inhibitors to mammalian target of rapamycin inhibitors in kidney transplant recipients: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2025.100958_bb0165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2025.100958_bb0170","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/TP.0b013e3181a23cb2","article-title":"The challenge of achieving target drug concentrations in clinical trials: experience from the symphony study","volume":"87","author":"Ekberg","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100958_bb0175","doi-asserted-by":"crossref","first-page":"372","DOI":"10.23876\/j.krcp.21.207","article-title":"Elderly kidney transplant recipients have favorable outcomes but increased infection-related mortality","volume":"41","author":"Lim","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.trre.2025.100958_bb0180","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/ajt.16290","article-title":"Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort","volume":"21","author":"Davis","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100958_bb0185","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-199610150-00009","article-title":"Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation","volume":"62","author":"Kershner","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100958_bb0190","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00007890-199610150-00005","article-title":"An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States multicenter FK506 kidney transplant group","volume":"62","author":"Laskow","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100958_bb0195","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2025.100958_bb0200","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/ndt\/gfw394","article-title":"Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation","volume":"32","author":"Rozen-Zvi","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2025.100958_bb0205","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/FTD.0b013e3181a8f02a","article-title":"Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection","volume":"31","author":"Borobia","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2025.100958_bb0210","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/TP.0b013e3182461288","article-title":"Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium","volume":"93","author":"Jacobson","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100958_bb0215","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.transproceed.2011.02.047","article-title":"Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen","volume":"43","author":"Mecule","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2025.100958_bb0220","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/FTD.0b013e3182731809","article-title":"Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation","volume":"34","author":"Ro","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2025.100958_bb0225","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/ndt\/16.9.1905","article-title":"Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation","volume":"16","author":"Staatz","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2025.100958_bb0230","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.transproceed.2019.12.039","article-title":"Trough level and tacrolimus variability of early converted once-daily tacrolimus: 1-year follow-up study","volume":"52","author":"Sukkha","year":"2020","journal-title":"Transplant Proc"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:28:46Z","timestamp":1772825326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X25000588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0955470X25000588"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2025.100958","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of standard- versus reduced-dose tacrolimus exposure on clinical outcomes in adult kidney transplant recipients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2025.100958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100958"}}